Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Taisho presents the topoisomerase II inhibitor NCA-0424

June 16, 1998

Tricyclic compounds inhibiting abnormal cell growth discovered at Schering-Plough

June 16, 1998

Targeted Genetics' E1A gene therapy downregulates HER-2/neu oncogene in phase I

June 16, 1998

Vertex makes cancer drug available for licensing

June 16, 1998

AVI Biopharma offers oncology products for licensing

June 16, 1998

Spartaject busulfan enters phase I for treatment of neoplastic meningitis

June 15, 1998

Novartis selects somatostatin receptor-targeting antitumor compound for clinical testing

June 15, 1998

NeoPharm announces positive phase I clinical trial results with LED

June 15, 1998

Abarelix: a promising new treatment option for patients with prostate cancer

June 12, 1998

More on Ilex Oncology's chemopreventive agent

June 11, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...